New drug shows promise for rare blood cancer
NCT ID NCT02180724
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests acalabrutinib, a targeted drug, in 107 people with Waldenström macroglobulinemia, a rare blood cancer. The goal is to see how well the drug shrinks tumors and controls the disease. Participants either had prior treatment or are new to therapy and cannot take standard chemo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib
What this could lead to
If successful, this could provide a new treatment option for Waldenström macroglobulinemia that helps control the disease without chemotherapy.
What could go wrong
This is a mid-stage trial with only 107 participants, so results may not apply to everyone. The drug may not work as well in larger groups or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA (WM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Santa Barbara, California, 93105, United States
-
Research Site
Aurora, Colorado, 80012, United States
-
Research Site
Washington D.C., District of Columbia, 20007, United States
-
Research Site
Minneapolis, Minnesota, 55404, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Austin, Texas, 78705, United States
-
Research Site
Bedford, Texas, 76022, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Vancouver, Washington, 98684, United States
-
Research Site
Aurillac, 15002, France
-
Research Site
Clermond Ferrand, 63003, France
-
Research Site
Marseille, 13273, France
-
Research Site
Montpellier, 34295, France
-
Research Site
Nantes, 44093, France
-
Research Site
Paris, 75015, France
-
Research Site
Paris, 75651, France
-
Research Site
Pierre-Bénite, 69495, France
-
Research Site
Poitiers, 86021, France
-
Research Site
Reims, 51092, France
-
Research Site
Rennes, 35000, France
-
Research Site
Toulouse, 31059, France
-
Research Site
Vandœuvre-lès-Nancy, 54500, France
-
Research Site
Athens, 11528, Greece
-
Research Site
Bologna, 40138, Italy
-
Research Site
Milan, 20162, Italy
-
Research Site
Novara, 28100, Italy
-
Research Site
Amsterdam, 1105AZ, Netherlands
-
Research Site
Utrecht, 2508GA, Netherlands
-
Research Site
Salamanca, 37007, Spain
-
Research Site
Bournemouth, BH7 7DW, United Kingdom
-
Research Site
Leeds, LS9 7TF, United Kingdom
-
Research Site
Leicester, LE1 7RH, United Kingdom
-
Research Site
London, NW1 2BU, United Kingdom
-
Research Site
London, SW3 6JJ, United Kingdom
-
Research Site
Oxford, OX3 7LE, United Kingdom
-
Research Site
Plymouth, PL6 8DH, United Kingdom
-
Research Site
Southampton, SO16 6YD, United Kingdom